Bicocca Open Archive

Logo unimib boa
PUOTI, MASSIMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.299
EU - Europa 3.974
AS - Asia 2.387
AF - Africa 23
SA - Sud America 13
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 4
Totale 13.706
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.178
SG - Singapore 1.161
RU - Federazione Russa 826
IT - Italia 788
IE - Irlanda 758
SE - Svezia 659
HK - Hong Kong 615
DE - Germania 408
CN - Cina 305
ID - Indonesia 143
GB - Regno Unito 139
AT - Austria 97
CA - Canada 94
UA - Ucraina 85
FI - Finlandia 67
VN - Vietnam 54
IN - India 38
NL - Olanda 38
FR - Francia 33
TR - Turchia 33
MX - Messico 26
CZ - Repubblica Ceca 17
ES - Italia 16
DK - Danimarca 11
JP - Giappone 11
IR - Iran 9
BE - Belgio 8
PL - Polonia 8
ET - Etiopia 7
BR - Brasile 5
GR - Grecia 5
MU - Mauritius 5
EG - Egitto 4
KR - Corea 4
PH - Filippine 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AR - Argentina 3
AU - Australia 3
CL - Cile 3
NZ - Nuova Zelanda 3
IL - Israele 2
KZ - Kazakistan 2
NG - Nigeria 2
RO - Romania 2
UG - Uganda 2
AM - Armenia 1
BD - Bangladesh 1
BG - Bulgaria 1
BY - Bielorussia 1
CH - Svizzera 1
CR - Costa Rica 1
CY - Cipro 1
EC - Ecuador 1
EE - Estonia 1
EU - Europa 1
KG - Kirghizistan 1
LU - Lussemburgo 1
MD - Moldavia 1
MK - Macedonia 1
PE - Perù 1
PT - Portogallo 1
SI - Slovenia 1
TH - Thailandia 1
TN - Tunisia 1
TW - Taiwan 1
ZA - Sudafrica 1
ZM - Zambia 1
Totale 13.706
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.080
Singapore 1.033
Dublin 750
Hong Kong 615
Fairfield 591
Chandler 479
Houston 396
New York 390
Woodbridge 383
Princeton 379
Frankfurt am Main 325
Ashburn 324
Santa Clara 314
Wilmington 281
Seattle 220
Cambridge 196
Altamura 191
Milan 190
Lawrence 186
Jakarta 143
Jacksonville 111
San Diego 106
Dearborn 103
Vienna 74
Shanghai 68
Andover 64
Dong Ket 45
Beijing 43
London 42
Nanjing 40
Rome 40
Toronto 35
Falls Church 30
Lachine 28
Helsinki 26
Nuremberg 26
Hangzhou 24
Norwalk 22
Fremont 20
Guangzhou 20
Boardman 18
Cuauhtémoc 17
Los Angeles 15
Pune 15
Lappeenranta 13
Florence 12
Olomouc 12
Chicago 11
Ottawa 11
Redmond 11
Shenyang 11
Tianjin 11
Turin 11
Dallas 10
Madrid 10
Washington 10
Hebei 9
Jinan 9
Kilburn 9
San Mateo 9
Brussels 8
Lissone 8
Tokyo 8
Mumbai 7
Amsterdam 6
Bergamo 6
Cologno Monzese 6
Desio 6
Hounslow 6
Hyderabad 6
Mountain View 6
Nanchang 6
Ancona 5
Brno 5
Carate Brianza 5
Como 5
Groningen 5
Leawood 5
Naples 5
Parma 5
Winnipeg 5
Athens 4
Bologna 4
Bolzano 4
Bovisio Masciago 4
Chengdu 4
Islington 4
Munich 4
Prescot 4
Trumbull 4
Umeå 4
Weimar 4
Zhengzhou 4
Aachen 3
Auburn Hills 3
Birmingham 3
Brugherio 3
Changsha 3
Chiswick 3
Clearwater 3
Totale 9.860
Salva come PNG Salva come JPEG
Nome #
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 212
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 202
Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: Results from the Icona Foundation study 197
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 193
Estimating minimum adult HIV prevalence: A cross-sectional study to assess the characteristics of people living with HIV in Italy 174
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 174
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 173
Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: Results from a large multicentre observational prospective cohort (SCOLTA) 169
Characteristics and Clinical Implications of Carbapenemase-Producing Klebsiella pneumoniae Colonization and Infection, Italy 168
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study 166
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure 161
Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program 155
Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis c coinfection: Data from the ICONA foundation cohort 150
Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study 150
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 150
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 149
Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy 147
ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients 138
Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients 138
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 135
24 HOUR ARTERIAL DISTENSIBILITY IS RELATED WITH ABPM NON-DIPPING PATTERN IN HIVPOSITIVE PATIENTS 133
Successful pre- and posttransplant sofosbuvir-based anti-hepatitis C virus treatment in persons living with human immunodeficiency virus infection 130
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C 129
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 126
Mild Course of SARS-CoV-2 Infection in a Liver Transplant Recipient Undergoing Plasma Exchange and Defibrotide for Acute Graft Rejection 118
Risk of severe non AIDS events is increased among patients unable to increase their CD4 + T-cell counts >200+/μl despite effective HAART 117
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013 116
24-Hour Blood Pressure Monitoring Patterns in HIV-Positive Patients and its Relationship with Arterial Distensibility 113
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 113
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons 112
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 111
Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy 111
Factors Influencing Depression Endpoints Research (FINDER): Baseline results of Italian patients with depression 109
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011 109
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014 105
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 103
Impact of immunosuppressive therapy on the severity of COVID-19 in solid organ transplant recipients 103
HIV-positive to HIV-positive liver transplantation: To be continued 102
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 100
Clinical outcome in solid organ transplant recipients with COVID-19: A single-center experience 99
COVID-19 in liver transplant candidates: Pretransplant and post-transplant outcomes - An ELITA/ELTR multicentre cohort study 97
Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: A longitudinal study 94
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 93
Trends in all-cause mortality of hospitalized patients due to SARS-CoV-2 infection from a monocentric cohort in Milan (Lombardy, Italy) 92
An update on integrase inhibitors: New opportunities for a personalized therapy?: The NEXTaim Project 91
Sustained virological response with 16-week glecaprevir/pibrentasvir after failure to sofosbuvir/velpatasvir in post-transplant severe HCV recurrence in HIV 87
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C 87
24-hours arterial distensibility is related with ABPM non-dipping pattern in HIV-positive patients 86
Home-based COVID 19 management: A consensus document from Italian general medical practitioners and hospital consultants in the Lombardy region (Italy) 82
HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects from the ICONA Italian Cohort of HIV-Infected Patients 81
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials 80
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 80
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 78
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination 74
SARS-CoV-2 RNA in plasma samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study 74
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 74
Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV 73
HEFFICON: HIV effectiveness Italian conference 71
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: Results from the Italian EPOKA-MASTER cohort 71
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients 70
Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: Results from the EPOKA-MASTER cohort 70
Single-center outbreak of Pneumocystis jirovecii pneumonia in heart transplant recipients 68
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 67
Neurological manifestations in patients hospitalized with COVID-19: A retrospective analysis from a large cohort in Northern Italy 67
The use of molecular assays in the management of viral hepatitis 67
What is the impact of SARS-CoV-2 pandemic on antimicrobial stewardship programs (ASPs)? The results of a survey among a regional network of infectious disease centres 65
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 65
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 61
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. 61
Management of infections pre- and post-liver transplantation: report of an AISF consensus conference 61
Successful recovery from severe COVID-19 pneumonia after kidney transplantation: The interplay between immunosuppression and novel therapy including tocilizumab 60
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 60
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 60
Risk factors and clinical characteristics associated with hospitalization for community-acquired bacterial pneumonia in HIV-positive patients according to the presence of liver cirrhosis 60
Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy 60
Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress? 59
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry 59
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? 58
Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis 58
Detection and quantification of SARS-CoV-2 by droplet digital PCR in real-time PCR negative nasopharyngeal swabs from suspected COVID-19 patients 57
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients with Lymphoproliferative Disorders on BTKi 56
CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: A multinational, multicohort European study 55
Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop 55
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting 54
Prophylaxis and treatment of hepatitis B in immunocompromised patients 54
Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study 53
Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation—a position paper 52
Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin in patients with chronic hepatitis C virus genotype 1 infection receiving opioid substitution therapy: A post hoc analysis of 12 clinical trials 52
Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study 52
EASL recommendations on treatment of hepatitis C: Final update of the series☆ 52
Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation 52
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 52
Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study 52
Implementation of HCV screening in the 1969-1989 birth-cohort undergoing COVID-19 vaccination 51
Cerebral Infectious Opportunistic Lesions in a Patient with Acute Myeloid Leukaemia: The Challenge of Diagnosis and Clinical Management 51
Letter: sustained virological response and liver healing 51
Real life experiences in HCV management in 2018 51
Sex differences in electrolyte imbalances caused by SARS-CoV-2: A cross-sectional study 51
Corrigendum to “Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV” [J Hepatol 68 (2018) 33–41](S0168827817322596)(10.1016/j.jhep.2017.08.019) 50
Recommendations for the use of hepatitis C virus protease inhibitors for the treatment of chronic hepatitis C in HIV-infected persons. A position paper of the Italian Association for the Study of Infectious and Tropical Disease 50
Totale 9.484
Salva come PNG Salva come JPEG
Categoria #
all - tutte 82.287
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 82.287
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020403 0 0 0 0 0 0 69 79 80 46 89 40
2020/20211.907 64 114 89 102 117 113 125 389 267 156 204 167
2021/20221.821 73 108 261 174 85 119 42 270 125 100 86 378
2022/20232.602 463 748 231 174 112 429 24 139 162 21 68 31
2023/20242.557 51 63 78 69 344 590 440 55 291 47 100 429
2024/20253.670 511 1.151 429 375 655 336 213 0 0 0 0 0
Totale 14.649